Investigators Are Assessing an Experimental Interleukin-2 Drug in Patients With Metastatic Melanoma
Source: Cancer Network, July 2019
An international, randomized, open-label phase III study comparing the efficacy and safety of nivolumab plus bempegaldesleukin—an experimental interleukin (IL)-2–based drug—vs nivolumab monotherapy in patients with previously untreated, unresectable, or metastatic melanoma is now enrolling participants. The study design (abstract TPS9601) was presented during a poster session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago.
Though high-dose IL-2 monotherapy is effective and can even be curative in patients with metastatic melanoma, its use has largely been replaced by newer, more effective, immunotherapy treatments due to its poor toxicity profile and need for inpatient hospital administration, explained Sznol.